( SUNNYVALE Calif. April 11 2007 /PRN...)Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds,Health

SUNNYVALE, Calif., April 11, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today multiple presentations regarding its novel histone deacetylase (HDAC) inhibitor and Bruton's tyrosine kinase inhibitor compounds. The presentations will take place at the American Association for Cancer Research (AACR) 2007 Annual Meeting being held April 14-18, 2007, at the Los Angeles Convention Center, in Los Angeles, CA.

    The presentations are as follows:


    Sunday, April 15, 2007

    Session: HDAC Inhibitors 1

    Poster Presentation: Mechanisms of sensitivity in primary hematopoietic

    tumors and tumor lines to a novel HDAC inhibitor PCI-24781

    Abstract #678:  8:00 a.m. -12:00 p.m.

    Presenter:  Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.


    Session: HDAC Inhibitors 1

    Poster Presentation: Radiosensitization by the HDAC inhibitor PCI-24781 in

    SiHa and WiDr human tumor cell lines

    Abstract #695:  8:00 a.m. -12:00 p.m.

    Presenter:  Peggy L. Olive, Ph.D., British Columbia Cancer Research Center


    Monday, April 16, 2007

    Session: Targeted Agents and Other Novel Therapies

    Poster Presentation: Identification of cross-validated functional

    biomarkers for a novel HDAC inhibitor PCI-24781, and their utility for

    selection of clinical indications

    Abstract #1830:  8:00 a.m. -12:00 p.m.

    Presenter:  Sriram Balasubramanian, Ph.D., Pharmacyclics, Inc.


    Session: DNA Repair and Chemotherapeutic Agent Resistance

    Poster Presentation: Novel histone deacetylase (HDAC) inhibitor PCI-24781

    disrupts RAD51 foci and inhibits homologous recombination

    Abstract #1966:  8:00 a.m. -12:00 p.m.

    Presenter:  Shanthi Adimoolam, Ph.D., Pharmacyclics, Inc.


    Wednesday, April 18, 2007

    Session: Kinases 1

    Poster Presentation: PCI-31523: An irreversible inhibitor of Bruton's

    tyrosine kinase (Btk) that disrupts B cell receptor (BCR) signaling, is

    cytotoxic to B cell lympho
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2
Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat
Recurrent Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Promising Results From Phase 2 Clinical
Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung
Cancer
3. Pharmacyclics Announces Presentations and Published Abstracts on
Xcytrin at The 2007 American Society of Clinical Oncology Annual
Meeting
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC
Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with
Brutons Tyrosine Kinase Inhibitors
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone